- IBDEI35K ; ; 04-FEB-2020
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,50342,0)
- ;;=E89.6^^193^2490^29
- ;;^UTILITY(U,$J,358.3,50342,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50342,1,3,0)
- ;;=3^PostProcedural Adrenocortical Hypofunction
- ;;^UTILITY(U,$J,358.3,50342,1,4,0)
- ;;=4^E89.6
- ;;^UTILITY(U,$J,358.3,50342,2)
- ;;=^5003042
- ;;^UTILITY(U,$J,358.3,50343,0)
- ;;=L68.0^^193^2490^6
- ;;^UTILITY(U,$J,358.3,50343,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50343,1,3,0)
- ;;=3^Hirsutism
- ;;^UTILITY(U,$J,358.3,50343,1,4,0)
- ;;=4^L68.0
- ;;^UTILITY(U,$J,358.3,50343,2)
- ;;=^5009262
- ;;^UTILITY(U,$J,358.3,50344,0)
- ;;=M80.00XA^^193^2490^2
- ;;^UTILITY(U,$J,358.3,50344,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50344,1,3,0)
- ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
- ;;^UTILITY(U,$J,358.3,50344,1,4,0)
- ;;=4^M80.00XA
- ;;^UTILITY(U,$J,358.3,50344,2)
- ;;=^5013363
- ;;^UTILITY(U,$J,358.3,50345,0)
- ;;=M81.0^^193^2490^3
- ;;^UTILITY(U,$J,358.3,50345,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50345,1,3,0)
- ;;=3^Age-Related Osteoporosis w/o Fx
- ;;^UTILITY(U,$J,358.3,50345,1,4,0)
- ;;=4^M81.0
- ;;^UTILITY(U,$J,358.3,50345,2)
- ;;=^5013555
- ;;^UTILITY(U,$J,358.3,50346,0)
- ;;=M85.80^^193^2490^26
- ;;^UTILITY(U,$J,358.3,50346,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50346,1,3,0)
- ;;=3^Osteopenia,Unspec Site
- ;;^UTILITY(U,$J,358.3,50346,1,4,0)
- ;;=4^M85.80
- ;;^UTILITY(U,$J,358.3,50346,2)
- ;;=^5014473
- ;;^UTILITY(U,$J,358.3,50347,0)
- ;;=N62.^^193^2490^5
- ;;^UTILITY(U,$J,358.3,50347,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50347,1,3,0)
- ;;=3^Gynecomastia
- ;;^UTILITY(U,$J,358.3,50347,1,4,0)
- ;;=4^N62.
- ;;^UTILITY(U,$J,358.3,50347,2)
- ;;=^5015790
- ;;^UTILITY(U,$J,358.3,50348,0)
- ;;=E66.3^^193^2490^27
- ;;^UTILITY(U,$J,358.3,50348,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50348,1,3,0)
- ;;=3^Overweight
- ;;^UTILITY(U,$J,358.3,50348,1,4,0)
- ;;=4^E66.3
- ;;^UTILITY(U,$J,358.3,50348,2)
- ;;=^5002830
- ;;^UTILITY(U,$J,358.3,50349,0)
- ;;=E89.1^^193^2490^31
- ;;^UTILITY(U,$J,358.3,50349,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50349,1,3,0)
- ;;=3^Postprocedural Hypoinsulinemia
- ;;^UTILITY(U,$J,358.3,50349,1,4,0)
- ;;=4^E89.1
- ;;^UTILITY(U,$J,358.3,50349,2)
- ;;=^5003036
- ;;^UTILITY(U,$J,358.3,50350,0)
- ;;=R73.03^^193^2490^33
- ;;^UTILITY(U,$J,358.3,50350,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50350,1,3,0)
- ;;=3^Pre-Diabetes
- ;;^UTILITY(U,$J,358.3,50350,1,4,0)
- ;;=4^R73.03
- ;;^UTILITY(U,$J,358.3,50350,2)
- ;;=^8295662
- ;;^UTILITY(U,$J,358.3,50351,0)
- ;;=E73.9^^193^2490^18
- ;;^UTILITY(U,$J,358.3,50351,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50351,1,3,0)
- ;;=3^Lactose Intolerance,Unspec
- ;;^UTILITY(U,$J,358.3,50351,1,4,0)
- ;;=4^E73.9
- ;;^UTILITY(U,$J,358.3,50351,2)
- ;;=^5002914
- ;;^UTILITY(U,$J,358.3,50352,0)
- ;;=H40.9^^193^2491^11
- ;;^UTILITY(U,$J,358.3,50352,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50352,1,3,0)
- ;;=3^Glaucoma,Unspec
- ;;^UTILITY(U,$J,358.3,50352,1,4,0)
- ;;=4^H40.9
- ;;^UTILITY(U,$J,358.3,50352,2)
- ;;=^5005931
- ;;^UTILITY(U,$J,358.3,50353,0)
- ;;=H26.9^^193^2491^7
- ;;^UTILITY(U,$J,358.3,50353,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50353,1,3,0)
- ;;=3^Cataract,Unspec
- ;;^UTILITY(U,$J,358.3,50353,1,4,0)
- ;;=4^H26.9
- ;;^UTILITY(U,$J,358.3,50353,2)
- ;;=^5005363
- ;;^UTILITY(U,$J,358.3,50354,0)
- ;;=H10.9^^193^2491^10
- ;;^UTILITY(U,$J,358.3,50354,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50354,1,3,0)
- ;;=3^Conjunctivitis,Unspec
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI35K 3750 printed Jan 18, 2025@03:43:25 Page 2
- IBDEI35K ; ; 04-FEB-2020
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,50342,0)
- +2 ;;=E89.6^^193^2490^29
- +3 ;;^UTILITY(U,$J,358.3,50342,1,0)
- +4 ;;=^358.31IA^4^2
- +5 ;;^UTILITY(U,$J,358.3,50342,1,3,0)
- +6 ;;=3^PostProcedural Adrenocortical Hypofunction
- +7 ;;^UTILITY(U,$J,358.3,50342,1,4,0)
- +8 ;;=4^E89.6
- +9 ;;^UTILITY(U,$J,358.3,50342,2)
- +10 ;;=^5003042
- +11 ;;^UTILITY(U,$J,358.3,50343,0)
- +12 ;;=L68.0^^193^2490^6
- +13 ;;^UTILITY(U,$J,358.3,50343,1,0)
- +14 ;;=^358.31IA^4^2
- +15 ;;^UTILITY(U,$J,358.3,50343,1,3,0)
- +16 ;;=3^Hirsutism
- +17 ;;^UTILITY(U,$J,358.3,50343,1,4,0)
- +18 ;;=4^L68.0
- +19 ;;^UTILITY(U,$J,358.3,50343,2)
- +20 ;;=^5009262
- +21 ;;^UTILITY(U,$J,358.3,50344,0)
- +22 ;;=M80.00XA^^193^2490^2
- +23 ;;^UTILITY(U,$J,358.3,50344,1,0)
- +24 ;;=^358.31IA^4^2
- +25 ;;^UTILITY(U,$J,358.3,50344,1,3,0)
- +26 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
- +27 ;;^UTILITY(U,$J,358.3,50344,1,4,0)
- +28 ;;=4^M80.00XA
- +29 ;;^UTILITY(U,$J,358.3,50344,2)
- +30 ;;=^5013363
- +31 ;;^UTILITY(U,$J,358.3,50345,0)
- +32 ;;=M81.0^^193^2490^3
- +33 ;;^UTILITY(U,$J,358.3,50345,1,0)
- +34 ;;=^358.31IA^4^2
- +35 ;;^UTILITY(U,$J,358.3,50345,1,3,0)
- +36 ;;=3^Age-Related Osteoporosis w/o Fx
- +37 ;;^UTILITY(U,$J,358.3,50345,1,4,0)
- +38 ;;=4^M81.0
- +39 ;;^UTILITY(U,$J,358.3,50345,2)
- +40 ;;=^5013555
- +41 ;;^UTILITY(U,$J,358.3,50346,0)
- +42 ;;=M85.80^^193^2490^26
- +43 ;;^UTILITY(U,$J,358.3,50346,1,0)
- +44 ;;=^358.31IA^4^2
- +45 ;;^UTILITY(U,$J,358.3,50346,1,3,0)
- +46 ;;=3^Osteopenia,Unspec Site
- +47 ;;^UTILITY(U,$J,358.3,50346,1,4,0)
- +48 ;;=4^M85.80
- +49 ;;^UTILITY(U,$J,358.3,50346,2)
- +50 ;;=^5014473
- +51 ;;^UTILITY(U,$J,358.3,50347,0)
- +52 ;;=N62.^^193^2490^5
- +53 ;;^UTILITY(U,$J,358.3,50347,1,0)
- +54 ;;=^358.31IA^4^2
- +55 ;;^UTILITY(U,$J,358.3,50347,1,3,0)
- +56 ;;=3^Gynecomastia
- +57 ;;^UTILITY(U,$J,358.3,50347,1,4,0)
- +58 ;;=4^N62.
- +59 ;;^UTILITY(U,$J,358.3,50347,2)
- +60 ;;=^5015790
- +61 ;;^UTILITY(U,$J,358.3,50348,0)
- +62 ;;=E66.3^^193^2490^27
- +63 ;;^UTILITY(U,$J,358.3,50348,1,0)
- +64 ;;=^358.31IA^4^2
- +65 ;;^UTILITY(U,$J,358.3,50348,1,3,0)
- +66 ;;=3^Overweight
- +67 ;;^UTILITY(U,$J,358.3,50348,1,4,0)
- +68 ;;=4^E66.3
- +69 ;;^UTILITY(U,$J,358.3,50348,2)
- +70 ;;=^5002830
- +71 ;;^UTILITY(U,$J,358.3,50349,0)
- +72 ;;=E89.1^^193^2490^31
- +73 ;;^UTILITY(U,$J,358.3,50349,1,0)
- +74 ;;=^358.31IA^4^2
- +75 ;;^UTILITY(U,$J,358.3,50349,1,3,0)
- +76 ;;=3^Postprocedural Hypoinsulinemia
- +77 ;;^UTILITY(U,$J,358.3,50349,1,4,0)
- +78 ;;=4^E89.1
- +79 ;;^UTILITY(U,$J,358.3,50349,2)
- +80 ;;=^5003036
- +81 ;;^UTILITY(U,$J,358.3,50350,0)
- +82 ;;=R73.03^^193^2490^33
- +83 ;;^UTILITY(U,$J,358.3,50350,1,0)
- +84 ;;=^358.31IA^4^2
- +85 ;;^UTILITY(U,$J,358.3,50350,1,3,0)
- +86 ;;=3^Pre-Diabetes
- +87 ;;^UTILITY(U,$J,358.3,50350,1,4,0)
- +88 ;;=4^R73.03
- +89 ;;^UTILITY(U,$J,358.3,50350,2)
- +90 ;;=^8295662
- +91 ;;^UTILITY(U,$J,358.3,50351,0)
- +92 ;;=E73.9^^193^2490^18
- +93 ;;^UTILITY(U,$J,358.3,50351,1,0)
- +94 ;;=^358.31IA^4^2
- +95 ;;^UTILITY(U,$J,358.3,50351,1,3,0)
- +96 ;;=3^Lactose Intolerance,Unspec
- +97 ;;^UTILITY(U,$J,358.3,50351,1,4,0)
- +98 ;;=4^E73.9
- +99 ;;^UTILITY(U,$J,358.3,50351,2)
- +100 ;;=^5002914
- +101 ;;^UTILITY(U,$J,358.3,50352,0)
- +102 ;;=H40.9^^193^2491^11
- +103 ;;^UTILITY(U,$J,358.3,50352,1,0)
- +104 ;;=^358.31IA^4^2
- +105 ;;^UTILITY(U,$J,358.3,50352,1,3,0)
- +106 ;;=3^Glaucoma,Unspec
- +107 ;;^UTILITY(U,$J,358.3,50352,1,4,0)
- +108 ;;=4^H40.9
- +109 ;;^UTILITY(U,$J,358.3,50352,2)
- +110 ;;=^5005931
- +111 ;;^UTILITY(U,$J,358.3,50353,0)
- +112 ;;=H26.9^^193^2491^7
- +113 ;;^UTILITY(U,$J,358.3,50353,1,0)
- +114 ;;=^358.31IA^4^2
- +115 ;;^UTILITY(U,$J,358.3,50353,1,3,0)
- +116 ;;=3^Cataract,Unspec
- +117 ;;^UTILITY(U,$J,358.3,50353,1,4,0)
- +118 ;;=4^H26.9
- +119 ;;^UTILITY(U,$J,358.3,50353,2)
- +120 ;;=^5005363
- +121 ;;^UTILITY(U,$J,358.3,50354,0)
- +122 ;;=H10.9^^193^2491^10
- +123 ;;^UTILITY(U,$J,358.3,50354,1,0)
- +124 ;;=^358.31IA^4^2
- +125 ;;^UTILITY(U,$J,358.3,50354,1,3,0)
- +126 ;;=3^Conjunctivitis,Unspec